NCT03220217 - To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 26, 2017

Primary Completion Date

July 25, 2019

Study Completion Date

August 5, 2019

Conditions

Gastro-Enteropancreatic Neuroendocrine Tumor

Interventions

DRUG

Satoreotide trizoxetan 5-20μg

Positron emission tomography (PET) imaging agent

DRUG

Satoreotide trizoxetan 30-45μg

Positron emission tomography (PET) imaging agent

Trial Locations (5)

UCLA Medical Center, Los Angeles

Medical University of Innsbruck, Innsbruck

University Clinic for Radiology and Nuclear Medicine, Vienna

Aarhus University Hospital, Aarhus

Rigshospitalet, University of Copenhagen, Copenhagen